Successful First-In-Human Implantation of the BiVACOR Total Artificial Heart by Baylor and THI Doctors
July 26, 2024
July 26, 2024
HOUSTON, Texas, July 26 -- The Baylor College of Medicine issued the following news on July 25, 2024:
The Texas Heart Institute (THI), BiVACOR(R), a clinical-stage medical device company, Baylor St. Luke's Medical Center and Baylor College of Medicine announced today the successful first-in-human implantation of the BiVACOR Total Artificial Heart (TAH) as part of the U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS) on July 9, 2024. BiVACOR's TAH is a titanium-co . . .
The Texas Heart Institute (THI), BiVACOR(R), a clinical-stage medical device company, Baylor St. Luke's Medical Center and Baylor College of Medicine announced today the successful first-in-human implantation of the BiVACOR Total Artificial Heart (TAH) as part of the U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS) on July 9, 2024. BiVACOR's TAH is a titanium-co . . .